Life Sciences Licensing and Strategic Transactions

From securing business-critical financing to entering transformative R&D partnerships, licensing and strategic transactions are essential for driving growth and success in life sciences. We’re here to creatively draft, negotiate, execute, and manage your most strategic engagements to maximize opportunity at all stages of your product lifecycle.

Life sciences licensing and strategic transactions require multidimensional counsel to help navigate a broad range of legal topics ranging from IP and regulatory to tax and antitrust. Our deep bench of life sciences-savvy lawyers across renowned practices delivers the right mix of knowledge, no matter the challenge. From the moment you consider engaging in a collaborative relationship or financing arrangement, we work to deliver strategic, value-added counsel at every stage.

• Alfasigma, a global pharmaceutical company focused on specialty care and rare diseases, in its licensing agreement with GSK granting worldwide exclusive rights to linerixibat, a next-generation rare disease therapy.
• TG Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on therapies for B-cell diseases, in connection with a US$650 million ex-US commercialization agreement with Neuraxpharm Group for BRIUMVI®.
• Vertex Pharmaceuticals, a global biotechnology company focused on transformative medicines for serious diseases, in connection with a global manufacturing and strategic collaboration agreement with Lonza for stem cell-derived therapies for type 1 diabetes.
• Pfizer, a global biopharmaceutical company, in the structuring and negotiation of a non-exclusive licensing arrangement for its COVID-19 oral antiviral through the Medicines Patent Pool.
• The Trustees of the University of Pennsylvania, a leading research university and academic medical center, in connection with exclusive licensing, collaboration, sponsored research, and option agreements involving gene therapy and gene editing technologies.
• Taysha Gene Therapies, a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system, in connection with licensing and inventory purchase agreements for ABO-202.
• Launch Therapeutics, a clinical development company focused on accelerating the advancement of innovative therapies, in the formation of an SPV established to provide up to US$106 million in non-dilutive financing for clinical trials by Pathalys Pharma, Inc.
• Liquidia Technologies, Inc., a biopharmaceutical company focused on developing and commercializing products for patients with rare cardiopulmonary diseases, in connection with its Revenue Interest Financing Agreement with HealthCare Royalty for up to US$100 million.
• Sanofi, a global biopharmaceutical company, in the carve-out and operational agreements supporting the industrial disentanglement of Opella businesses across multiple jurisdictions.
• Intercept Pharmaceuticals, a biopharmaceutical company focused on liver diseases, in the US$450 million sale of certain foreign subsidiaries and rights relating to its international operations to Advanz Pharma.